Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer

World Journal of Gastroenterology : WJG
Han-Zhang ZhuChang-Ku Jia

Abstract

Liver cancer has a high mortality and morbidity rate throughout the world. In clinical practice, the prognosis of liver cancer patients is poor, and the complex reasons contribute to treatment failures, including fibrosis, hepatitis viral infection, drug resistance and metastasis. Thus, screening novel prognostic biomarkers is of great importance for guiding liver cancer therapy. Orosomucoid genes (ORMs) encode acute phase plasma proteins, including orosomucoid 1 (ORM1) and ORM2. Previous studies showed their upregulation upon inflammation, but the specific function of ORMs has not yet been determined, especially in the development of liver cancer. To determine the expression of ORMs and their potential function in liver cancer. Analysis of the expression of ORMs in different human tissues was performed on data from the HPA RNA-seq normal tissues project. The expression ratio of ORMs was determined using the HCCDB database, including the ratio between liver cancer and other cancers, normal liver and other normal tissues, liver cancer and adjacent normal liver tissues. Analysis of ORM expression in different cancer types was performed using The Cancer Genome Atlas and TIMER database. The expression of ORMs in liver tumor tissues...Continue Reading

References

Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Dec 14, 2006·International Journal of Cancer. Journal International Du Cancer·Tetsuo TakeharaNorio Hayashi
Feb 26, 2010·Nature·David K BreslowJonathan S Weissman
Mar 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sumin HanAmy Chang
Feb 14, 2012·Journal of Cell Science·Ming LiuAmy Chang
Mar 1, 2012·PloS One·Xuhua ZhangChuanxin Wang
Nov 30, 2012·Nucleic Acids Research·Tanya BarrettAlexandra Soboleva
Jun 27, 2013·Annals of Surgical Oncology·Ho-Yeong LimCheol-Keun Park
Jan 23, 2015·Genome Biology·Bo LiColin N Dewey
May 13, 2015·Canadian Journal of Gastroenterology & Hepatology·Alex GiakoustidisRoger Williams
Sep 1, 2015·PloS One·Wallax Augusto Silva FerreiraBárbara do Nascimento Borges
Jul 9, 2016·CNS Neuroscience & Therapeutics·Jing-Jing WanXia Liu
Oct 11, 2016·Current Pharmaceutical Design·Kaja Blagotinsek, Damjana Rozman
Dec 8, 2016·Cancer Research·Chellappagounder ThangavelRobert B Den
Feb 15, 2017·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Myungjin JoKyoungho Suk
Sep 22, 2017·Diseases·Marco Fernandes, Holger Husi
Oct 13, 2017·Nature·UNKNOWN GTEx ConsortiumStephen B Montgomery
Nov 24, 2017·Cancer Treatment Reviews·Nithya Krishnamurthy, Razelle Kurzrock
Sep 30, 2018·Genomics, Proteomics & Bioinformatics·Qiuyu LianJin Gu
Apr 27, 2019·Journal of Cellular Physiology·Jing-Jing WanXia Liu
May 6, 2019·Nature Reviews. Cancer·Lindsey N Kent, Gustavo Leone

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE14520
GSE36376

Methods Mentioned

BETA
RNA-seq

Software Mentioned

GEPIA
GEO
Gene Set Enrichment Analysis ( GSEA )
Diff Exp
2R
RSEM
TIMER
GSEA
GraphPad Prism

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.